Staring at a down quarter for Opdivo, Bristol Myers keeps its eyes on price competition potential in packed PD-1 market
Despite its standing as one of the bestselling anti-PD-1s, Bristol Myers Squibb can ill afford a down quarter for its leading I/O amid a packed — and growing — class. With Covid-19 already nipping at sales, the drugmaker is also keeping close watch for a potential discounted disrupter in the PD-1 class, which could come sooner rather than later.
Bristol Myers’ anti-PD-1 Opdivo posted disappointing sales for Opdivo in the first quarter, down 3% from the same time period last year at $1.72 billion, according to earnings released Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.